EODData

MEMBERSHIP REGISTER LOG IN

FRA, 328: MEIRAGTX HLDGSDL-0000388

21 Nov 2025
LAST:

6.350

CHANGE:
 0.15		OPEN:
6.350		HIGH:
6.350		ASK:
0.000		VOLUME:
230
CHG(%):
2.31		PREV:
6.500		LOW:
6.350		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
21 Nov 256.3506.3506.3506.350230
20 Nov 256.5006.5006.5006.500230
19 Nov 256.6006.8006.6006.800230
18 Nov 256.6506.6506.6506.650641
17 Nov 256.9506.9506.9506.950641
13 Nov 257.4007.4007.4007.400641
12 Nov 257.5507.9007.5507.900641
11 Nov 257.3007.3007.3007.30030
07 Nov 257.2007.2007.2007.20030
06 Nov 257.3507.3507.3507.35030

PROFILE

Name:MEIRAGTX HLDGSDL-0000388
About:MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Sector:Healthcare
Industry:Biotechnology
Address:450 East 29th Street, New York, NY, United States, 10016
Website:https://meiragtx.com
ISIN:KYG596651029
LEI:54930007YV6NYIOGFZ57

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-3.49 
Forward P/E:-3.99 
PEG Ratio:0.09 
Price to Sales:16.72 
Price to Book:209.46 
Profit Margin:0.29 
Operating Margin:-12.14 
Return on Assets:-0.42 
Return on Equity:-3.80 
Revenue:32.91M 
Shares:80.45M 
Market Cap:510.84M 

TECHNICAL INDICATORS

MA5:6.654.7%
MA10:7.0410.9%
MA20:7.2814.7%
MA50:6.939.2%
MA100:6.776.6%
MA200:6.212.2%
RSI14:26.56 
WPR14:-100.00 
MTM14:-1.25
ROC14:-0.16 
ATR:0.24 
Week High:6.959.4%
Week Low:6.350.0%
Month High:7.9024.4%
Month Low:6.352.2%
Year High:7.9024.4%
Year Low:4.0656.5%
Volatility:36.63